A Phase 1/2 interventional study of Autologous Bone Marrow CD34+ Stem Cells and Sham Therapy in Central Retinal Vein Occlusion, sponsored by The Emmes Company, LLC. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-02.
Sponsored by The Emmes Company, LLC · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies in Retinal Vein Occlusion with a site in United States — 6 open to participants now, 10 under way, 1 of them phase 3. Retinal Vein Occlusion · United States.
Among the 106 studies in Retinal Vein Occlusion with a site in United States, this one is the 69th largest by enrollment of the 90 interventional ones that give a count, is one of 8 that started in 2019, is one of 9 in phase 1/2, and was the 81st registered.
289 studies on the registry are indexed under Retinal Vein Occlusion; 32 are open to participants now.
Browse Retinal Vein Occlusion studies →6 of the 106 studies in Retinal Vein Occlusion with a site in United States are open now. Recruiting first, the newest first:
MediBeacon · Sites in United States
Ages 18+ · Healthy volunteers
EyeBiotech Ltd. · Sites in United States
Ages 18+
Johns Hopkins University · Sites in United States
Ages 18–99 · Healthy volunteers
National Eye Institute (NEI) · Sites in United States
Ages 2–120 · Healthy volunteers
Harrow Inc · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Retinal Vein Occlusion studies recruiting now, 13 (72%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 29 · Phase 3 25 · Phase 4 13
First in 2001; this study’s year is marked. 8 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 51 across 208 interventional studies indexed under Retinal Vein Occlusion.
Median enrollment 40 across the 90 interventional studies, 44 across the 16 observational. Of the 88 that completed or were terminated, 51 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 106 have an industry lead sponsor. The 10 most frequent:
The Emmes Company, LLC is the lead sponsor of 11 studies on the registry; none are open to participants now.
The Emmes Company, LLC has 3 studies filed under Retinal Vein Occlusion — fewer than ten, so there is no comparison to draw.
4 of the studies in Retinal Vein Occlusion with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05476926Hoffmann-La RocheA Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products | 2026-11-30 |
| NCT04008121MediBeaconFeasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium | 2026-12 |
| NCT07891910Retina Consultants of DelmarvaIopidine to Decrease Intraocular Pressure Rise After Injections | 2026-12-01 |
| NCT04505618Johns Hopkins UniversityOptical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease | 2027-06-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 106 studies in Retinal Vein Occlusion with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates whether intravitreal autologous CD34+ stem cell therapy is safe, feasible and potentially beneficial in eyes with vision loss from central retinal vein occlusion (CRVO). Half of the participants will receive immediate cellular therapy followed by sham therapy 6 months later, while the other half will receive immediate sham therapy followed by cellular therapy 6 months later. Participants will be followed for a total of 1 year.
The goal of this phase I/II prospective, randomized, sham-controlled, double-masked clinical trial is to determine whether intravitreal autologous CD34+ stem cell therapy is safe, feasible and potentially beneficial in eyes with vision loss from central retinal vein occlusion (CRVO). Retinal Vein Occlusion (RVO) is a leading retinal vascular cause of vision loss in the elderly. CD34+ stem cells in human bone marrow are mobilized into the circulation in response to tissue ischemia for tissue revascularization and repair. Since local delivery of CD34+ stem cells benefits ischemic tissue, intravitreal delivery of CD34+ stem cells may benefit vision and retinal ischemia in eyes with RVO. A pilot clinical trial has shown no major safety or feasibility concerns using intravitreal autologous CD34+ bone marrow stem cells. In this proposed expanded phase I/II study, 20 participants (20 eyes) with persistent vision loss from CRVO will be enrolled and followed for 1 year.
Participants will be randomized 1:1 to immediate cell therapy/deferred sham therapy or immediate sham therapy/deferred cell therapy. At month 6, the cell treated eye will receive sham treatment and the sham treated eye will get cell therapy. The cellular therapy involves bone marrow aspiration, isolation of CD34+ cells from the aspirate under Good Manufacturing Practice (GMP) conditions, and intravitreal injection of isolated CD34+ cells. The sham therapy involves a sham bone marrow aspiration with penetration of the skin but no penetration of the bone and a sham intravitreal injection without penetrating the eye. The participant, examining ophthalmologist, visual acuity examiner, photographers and OCT, perimetry, and electroretinography (ERG) technicians will remain masked to study treatment assignment for study duration. A comprehensive eye examination with ETDRS best-corrected visual acuity, optical coherence tomography (OCT) and OCT angiography (OCTA), autofluorescence, fundus photography, fluorescein angiography, microperimetry, and electroretinography will be performed at baseline and serially. A subset of participants with good fixation on microperimetry and clear media on exam and commercial-grade OCTA and who give consent will have ultra-high resolution cellular retinal imaging using research-grade OCT and OCTA and adaptive optics-OCT at baseline. Participants with high quality images will have repeat imaging at 1 month after stem cell treatment, with at least 2 of the participants randomized to the deferred cellular therapy arm also having imaging 1 month after sham therapy. Post-release flow cytometry characterization will be performed to determine the composition of the CD34+ enriched final product in terms of hematopoietic versus angiogenic stem cells based on cell surface markers (i.e., CD133(+)/CD45(+)/CD34(+) vs CD31(+)/VEGFR-2(+)/CD45(-)/CD34(+)). The long-term objective is to determine whether intravitreal autologous CD34+ cell therapy can minimize, or reverse vision loss associated with retinal ischemia without compromising safety.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Study Eye Inclusion/Exclusion Criteria:
Inclusion criteria for the study eye:
Exclusion criteria for the study eye:
Participant-level Inclusion/Exclusion Criteria:
Participant-level inclusion criteria:
Participant-level exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
At baseline: Bone marrow aspiration followed by intravitreal injection of CD34+ cells. At 6 months: Sham bone marrow aspiration and sham intravitreal injection.
Biological: Autologous Bone Marrow CD34+ Stem Cells · Biological: Sham Therapy
At baseline: Sham bone marrow aspiration followed by sham intravitreal injection. At 6 months: Bone marrow aspiration followed by intravitreal injection of CD34+ cells.
Biological: Autologous Bone Marrow CD34+ Stem Cells · Biological: Sham Therapy
Single intravitreal injection of autologous bone marrow CD34+ stem cells. The number of cells to be injected per eye will range from 800,000 to 10 million, depending on the yield of the bone marrow aspiration and the isolation procedure.
Sham bone marrow aspiration procedure that penetrates the skin, but does not penetrate the bone followed by sham intravitreal injection without penetration of the eye
Incidence and Severity of Ocular and Systemic Adverse Events
The primary safety outcome will be assessed at month 6. Adverse events (AE) that occur during the first 6 months of the trial will be broken down by whether the AE occurred following the sham or cellular treatment to assess differences in the adverse event experience between the cellular and sham therapies.
Time frame: Months 0 to 6
Feasibility of the Stem Cell Therapy
Number of CD34+ cells isolated from the bone marrow aspirate and number of cells injected into the eye
Time frame: Day 0 and Day 182
Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Letter Score
Mean change from baseline of visual acuity letter score at Month 6. The measure is calculated by subtracting the baseline visual acuity letter score from the month 6 visual acuity letter score. The participant is refracted for best corrected vision, and then reads single letters from the ETDRS charts using a visual acuity light box at a 4 meter distance (or 1 meter for participants with sufficiently reduced vision) according to a specific algorithm. A letter score is provided that ranges from 0 (unable to read any letters) to 100. A visual acuity letter score of 85 corresponds to a visual acuity of 20/20 as a Snellen equivalent. Higher is better.
Time frame: Months 0 to 6
Change in % Reduced Sensitivity
Mean change from baseline of % reduced sensitivity at Month 6 as measured by microperimetry (decrease is better)
Time frame: Months 0 to 6
Change in Average Threshold
Mean change from baseline of average threshold (dB) at Month 6 as measured by microperimetry (increase is better)
Time frame: Months 0 to 6
Change in Percent Normal Amplitude for ERG+OP (Oscillatory Potential) A-wave Under Scotopic Conditions
Mean change from baseline of percent of normal amplitude for ERG+OP a-wave under scotopic conditions at Month 6 as measured by Full-field ERG (increase is better)
Time frame: Months 0 to 6
Change in Percent Normal Amplitude for ERG+OP B-wave Under Scotopic Conditions
Mean change from baseline of percent of normal amplitude for ERG+OP b-wave under scotopic conditions at Month 6 as measured by Full-field ERG (increase is better)
Time frame: Months 0 to 6
Change in Percent Normal Latency of ERG+OP A-wave Under Scotopic Conditions
Mean change from baseline of percent normal latency of ERG+OP a-wave under scotopic conditions at Month 6 as measured by Full-field ERG (decrease is better)
Time frame: Months 0 to 6
Change in Percent Normal Latency of ERG+OP B-wave Under Scotopic Conditions
Mean change from baseline of percent normal latency of ERG+OP b-wave under scotopic conditions at Month 6 as measured by Full-field ERG (decrease is better)
Time frame: Months 0 to 6
Change in Percent Normal Amplitude for A-wave Under Photopic Conditions
Mean change from baseline of percent normal amplitude for a-wave under photopic conditions at Month 6 as measured by Full-field ERG (increase is better)
Time frame: Months 0 to 6
Change in Percent Normal Amplitude for B-wave Under Photopic Conditions
Mean change from baseline of percent normal amplitude for b-wave under photopic conditions at Month 6 as measured by Full-field ERG (increase is better)
Time frame: Months 0 to 6
Change in Percent Normal Latency for A-wave Under Photopic Conditions
Mean change from baseline of percent normal latency for a-wave under photopic conditions at Month 6 as measured by Full-field ERG (decrease is better)
Time frame: Months 0 to 6
Change in Percent Normal Latency for B-wave Under Photopic Conditions
Mean change from baseline of percent normal latency for b-wave under photopic conditions at Month 6 as measured by Full-field ERG (decrease is better)
Time frame: Months 0 to 6
Change in Percent Normal Flicker Amplitude
Mean change from baseline in percent normal flicker amplitude at Month 6 as measured by Full-field ERG (increase is better)
Time frame: Months 0 to 6
Change in Flicker Latency Trough
Mean change from baseline of latency trough at Month 6 as measured by Full-field ERG (decrease is better)
Time frame: Months 0 to 6
Change in Percent Normal Amplitude for A-wave Under Scotopic Conditions
Mean change from baseline of percent normal amplitude for a-wave under scotopic conditions at Month 6 as measured by Full-field ERG (increase is better)
Time frame: Months 0 to 6
Change in Percent Normal Latency of A-wave Under Scotopic Conditions
Mean change from baseline of percent normal latency of a-wave under scotopic conditions at Month 6 as measured by Full-field ERG (decrease is better)
Time frame: Months 0 to 6
Change in Percent Normal Amplitude for B-wave Under Scotopic Conditions
Mean change from baseline of percent normal amplitude for b-wave under scotopic conditions at Month 6 as measured by Full-field ERG (increase is better)
Time frame: Months 0 to 6
Change in Percent Normal Latency for B-wave Under Scotopic Conditions
Mean change from baseline of percent normal latency for b-wave under scotopic conditions at Month 6 as measured by Full-field ERG (decrease is better)
Time frame: Months 0 to 6
Foveal Avascular Zone Integrity
Number of study eyes in each of the following categories as it relates to the integrity of the foveal avascular zone: Intact, Questionable, Disrupted (\<900 microns), Disrupted (900-1800 microns), Disrupted (\>1800 microns), and Cannot grade. Measured at Month 6 by fluorescein angiogram
Time frame: 6 months
Change in Area of Non-perfusion Within ETDRS Grid
Mean change from baseline of area of non-perfusion within ETDRS grid at Month 6 as measured by fluorescein angiogram (decrease is better)
Time frame: Months 0 to 6
Change in Area of Non-perfusion Within Networc Grid
Mean change from baseline of area of non-perfusion within Networc grid at Month 6 as measured by fluorescein angiogram (decrease is better)
Time frame: Months 0 to 6
| Milestone | Immediate Cellular Therapy / Deferred Sham Therapy | Immediate Sham Therapy / Deferred Cellular Therapy |
|---|---|---|
| Started | 7 | 9 |
| Completed | 7 | 9 |
| Not completed | 0 | 0 |
The primary safety outcome will be assessed at month 6. Adverse events (AE) that occur during the first 6 months of the trial will be broken down by whether the AE occurred following the sham or cellular treatment to assess differences in the adverse event experience between the cellular and sham therapies.
| participants | Immediate Cellular Therapy / Deferred Sham Therapy | Immediate Sham Therapy / Deferred Cellular Therapy |
|---|---|---|
| Altered visual depth perception in study eye | 1 | 0 |
| Chalazion in study eye | 0 | 1 |
| Cystoid macular oedema in study eye | 0 | 1 |
| Dermatochalasis in study eye | 0 | 1 |
| Dry eye in study eye | 2 | 4 |
| Eye irritation in study eye | 5 | 4 |
| Eye pain in study eye | 4 | 2 |
| Eye puritis in study eye | 1 | 1 |
| Foreign body sensation in study eye | 2 | 3 |
| Meibomian gland dysfuntion in study eye | 1 | 1 |
| Ocular hyperaemia in study eye | 3 | 3 |
| Periorbital irritation in study eye | 0 | 1 |
| Photopsia in study eye | 0 | 1 |
| Presbyopia in study eye | 1 | 0 |
| Swelling of eyelid in study eye | 1 | 0 |
| Vision blurred in study eye | 1 | 1 |
| Visual acuity reduced in study eye | 0 | 1 |
| Visual impairment in study eye | 2 | 0 |
| Vitreous degeneration in study eye | 1 | 0 |
| Vitreous detachment in study eye | 1 | 0 |
| Vitreous floaters in study eye | 6 | 0 |
| Cystoid macular oedema in fellow eye | 0 | 1 |
| Visual impairment in fellow eye | 1 | 1 |
| Vitreous floaters in fellow eye | 1 | 1 |
| Abdominal pain upper | 0 | 1 |
| Acarodermatitis | 0 | 1 |
| Anaemia | 0 | 1 |
| Appendicitis | 0 | 1 |
| Arthralgia | 1 | 0 |
| Arthropod bite | 1 | 0 |
| Back pain | 1 | 1 |
| Basal cell carcinoma | 1 | 0 |
| Cholelithiasis | 1 | 0 |
| Chronic kidney disease | 1 | 0 |
| Dizziness | 1 | 0 |
| Epicondylitis | 0 | 1 |
| Fall | 0 | 3 |
| Foot deformity | 0 | 1 |
| Heat exhaustion | 0 | 1 |
| Hypertension | 2 | 0 |
| Immunisation reaction | 1 | 3 |
| Migraine | 0 | 1 |
| Neuralgia | 1 | 0 |
| Osteoarthritis | 1 | 0 |
| Pain in extremity | 1 | 0 |
| Palpitations | 1 | 0 |
| Procedural pain | 0 | 1 |
| Rash | 0 | 1 |
| Rectal haemorrhage | 0 | 1 |
| Rib fracture | 0 | 1 |
| Sciatica | 0 | 1 |
| Soft tissue mass | 1 | 0 |
| Squamous cell carcinoma of skin | 1 | 0 |
| Upper respiratory tract infection | 1 | 1 |
| White blood cell count decreased | 1 | 0 |
Number of CD34+ cells isolated from the bone marrow aspirate and number of cells injected into the eye
| Number of cells in millions | Immediate Cellular Therapy / Deferred Sham Therapy | Immediate Sham Therapy / Deferred Cellular Therapy |
|---|---|---|
| Number of CD34+ cells isolated from the bone marrow aspirate (pre-release) | 5.4 ± 2.20 | 5.9 ± 4.65 |
| Number of CD34+ cells injected into the eye (pre-release) | 3.8 ± 1.69 | 4.6 ± 4.14 |
Mean change from baseline of visual acuity letter score at Month 6. The measure is calculated by subtracting the baseline visual acuity letter score from the month 6 visual acuity letter score. The participant is refracted for best corrected vision, and then reads single letters from the ETDRS charts using a visual acuity light box at a 4 meter distance (or 1 meter for participants with sufficiently reduced vision) according to a specific algorithm. A letter score is provided that ranges from 0 (unable to read any letters) to 100. A visual acuity letter score of 85 corresponds to a visual acuity of 20/20 as a Snellen equivalent. Higher is better.
| Letters read | Immediate Cellular Therapy / Deferred Sham Therapy | Immediate Sham Therapy / Deferred Cellular Therapy |
|---|---|---|
| Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Letter Score | 1.7 ± 3.82 | 2.1 ± 10.98 |
Mean change from baseline of % reduced sensitivity at Month 6 as measured by microperimetry (decrease is better)
| percent reduced | Immediate Cellular Therapy / Deferred Sham Therapy | Immediate Sham Therapy / Deferred Cellular Therapy |
|---|---|---|
| Change in % Reduced Sensitivity | 0.8 ± 14.00 | -11.4 ± 16.81 |
Mean change from baseline of average threshold (dB) at Month 6 as measured by microperimetry (increase is better)
| dB | Immediate Cellular Therapy / Deferred Sham Therapy | Immediate Sham Therapy / Deferred Cellular Therapy |
|---|---|---|
| Change in Average Threshold | -1.2 ± 2.99 | 0.0 ± 3.83 |
Mean change from baseline of percent of normal amplitude for ERG+OP a-wave under scotopic conditions at Month 6 as measured by Full-field ERG (increase is better)
| percent normal amplitude | Immediate Cellular Therapy / Deferred Sham Therapy | Immediate Sham Therapy / Deferred Cellular Therapy |
|---|---|---|
| Change in Percent Normal Amplitude for ERG+OP (Oscillatory Potential) A-wave Under Scotopic Conditions | -7.7 ± 36.84 | 18.6 ± 18.15 |
Mean change from baseline of percent of normal amplitude for ERG+OP b-wave under scotopic conditions at Month 6 as measured by Full-field ERG (increase is better)
| percent normal amplitude | Immediate Cellular Therapy / Deferred Sham Therapy | Immediate Sham Therapy / Deferred Cellular Therapy |
|---|---|---|
| Change in Percent Normal Amplitude for ERG+OP B-wave Under Scotopic Conditions | -8.4 ± 48.94 | 11.6 ± 22.50 |
Mean change from baseline of percent normal latency of ERG+OP a-wave under scotopic conditions at Month 6 as measured by Full-field ERG (decrease is better)
| percent normal latency | Immediate Cellular Therapy / Deferred Sham Therapy | Immediate Sham Therapy / Deferred Cellular Therapy |
|---|---|---|
| Change in Percent Normal Latency of ERG+OP A-wave Under Scotopic Conditions | 1.3 ± 21.59 | -9.0 ± 8.33 |
Mean change from baseline of percent normal latency of ERG+OP b-wave under scotopic conditions at Month 6 as measured by Full-field ERG (decrease is better)
| percent normal latency | Immediate Cellular Therapy / Deferred Sham Therapy | Immediate Sham Therapy / Deferred Cellular Therapy |
|---|---|---|
| Change in Percent Normal Latency of ERG+OP B-wave Under Scotopic Conditions | 12.7 ± 42.38 | -1.2 ± 24.95 |
Mean change from baseline of percent normal amplitude for a-wave under photopic conditions at Month 6 as measured by Full-field ERG (increase is better)
| percent normal amplitude | Immediate Cellular Therapy / Deferred Sham Therapy | Immediate Sham Therapy / Deferred Cellular Therapy |
|---|---|---|
| Change in Percent Normal Amplitude for A-wave Under Photopic Conditions | 6.2 ± 35.84 | 26.8 ± 79.01 |
Mean change from baseline of percent normal amplitude for b-wave under photopic conditions at Month 6 as measured by Full-field ERG (increase is better)
| percent normal amplitude | Immediate Cellular Therapy / Deferred Sham Therapy | Immediate Sham Therapy / Deferred Cellular Therapy |
|---|---|---|
| Change in Percent Normal Amplitude for B-wave Under Photopic Conditions | -2.5 ± 21.83 | -6.0 ± 22.83 |
Mean change from baseline of percent normal latency for a-wave under photopic conditions at Month 6 as measured by Full-field ERG (decrease is better)
| percent normal latency | Immediate Cellular Therapy / Deferred Sham Therapy | Immediate Sham Therapy / Deferred Cellular Therapy |
|---|---|---|
| Change in Percent Normal Latency for A-wave Under Photopic Conditions | -3.5 ± 20.19 | -0.0 ± 13.08 |
Mean change from baseline of percent normal latency for b-wave under photopic conditions at Month 6 as measured by Full-field ERG (decrease is better)
| percent normal latency | Immediate Cellular Therapy / Deferred Sham Therapy | Immediate Sham Therapy / Deferred Cellular Therapy |
|---|---|---|
| Change in Percent Normal Latency for B-wave Under Photopic Conditions | -0.1 ± 10.26 | -4.7 ± 7.59 |
Mean change from baseline in percent normal flicker amplitude at Month 6 as measured by Full-field ERG (increase is better)
| percent normal flicker amplitude | Immediate Cellular Therapy / Deferred Sham Therapy | Immediate Sham Therapy / Deferred Cellular Therapy |
|---|---|---|
| Change in Percent Normal Flicker Amplitude | -10.8 ± 14.10 | 2.2 ± 15.08 |
Mean change from baseline of latency trough at Month 6 as measured by Full-field ERG (decrease is better)
| percent latency trough | Immediate Cellular Therapy / Deferred Sham Therapy | Immediate Sham Therapy / Deferred Cellular Therapy |
|---|---|---|
| Change in Flicker Latency Trough | -4.2 ± 8.92 | -0.3 ± 8.12 |
Mean change from baseline of percent normal amplitude for a-wave under scotopic conditions at Month 6 as measured by Full-field ERG (increase is better)
| percent normal amplitude | Immediate Cellular Therapy / Deferred Sham Therapy | Immediate Sham Therapy / Deferred Cellular Therapy |
|---|---|---|
| Change in Percent Normal Amplitude for A-wave Under Scotopic Conditions | 8.2 ± 42.65 | 3.8 ± 48.29 |
Mean change from baseline of percent normal latency of a-wave under scotopic conditions at Month 6 as measured by Full-field ERG (decrease is better)
| percent normal latency | Immediate Cellular Therapy / Deferred Sham Therapy | Immediate Sham Therapy / Deferred Cellular Therapy |
|---|---|---|
| Change in Percent Normal Latency of A-wave Under Scotopic Conditions | 12.4 ± 56.19 | -14.7 ± 24.81 |
Mean change from baseline of percent normal amplitude for b-wave under scotopic conditions at Month 6 as measured by Full-field ERG (increase is better)
| percent normal amplitude | Immediate Cellular Therapy / Deferred Sham Therapy | Immediate Sham Therapy / Deferred Cellular Therapy |
|---|---|---|
| Change in Percent Normal Amplitude for B-wave Under Scotopic Conditions | -1.7 ± 35.75 | 19.2 ± 34.67 |
Mean change from baseline of percent normal latency for b-wave under scotopic conditions at Month 6 as measured by Full-field ERG (decrease is better)
| percent normal latency | Immediate Cellular Therapy / Deferred Sham Therapy | Immediate Sham Therapy / Deferred Cellular Therapy |
|---|---|---|
| Change in Percent Normal Latency for B-wave Under Scotopic Conditions | -4.9 ± 12.32 | -5.7 ± 14.47 |
Number of study eyes in each of the following categories as it relates to the integrity of the foveal avascular zone: Intact, Questionable, Disrupted (\<900 microns), Disrupted (900-1800 microns), Disrupted (\>1800 microns), and Cannot grade. Measured at Month 6 by fluorescein angiogram
| Participants | Immediate Cellular Therapy / Deferred Sham Therapy | Immediate Sham Therapy / Deferred Cellular Therapy |
|---|---|---|
| Foveal Avascular Zone Integrity at Baseline — Intact | 0 | 1 |
| Foveal Avascular Zone Integrity at Baseline — Questionable | 2 | 2 |
| Foveal Avascular Zone Integrity at Baseline — Disrupted (<900 microns) | 1 | 2 |
| Foveal Avascular Zone Integrity at Baseline — Disrupted (900-1800 microns) | 1 | 4 |
| Foveal Avascular Zone Integrity at Baseline — Disrupted (>1800 microns) | 3 | 0 |
| Foveal Avascular Zone Integrity at Baseline — Cannot grade | 0 | 0 |
| Foveal Avascular Zone Integrity at Month 6 — Intact | 0 | 2 |
| Foveal Avascular Zone Integrity at Month 6 — Questionable | 2 | 0 |
| Foveal Avascular Zone Integrity at Month 6 — Disrupted (<900 microns) | 2 | 2 |
| Foveal Avascular Zone Integrity at Month 6 — Disrupted (900-1800 microns) | 2 | 4 |
| Foveal Avascular Zone Integrity at Month 6 — Disrupted (>1800 microns) | 1 | 0 |
| Foveal Avascular Zone Integrity at Month 6 — Cannot grade | 0 | 1 |
Mean change from baseline of area of non-perfusion within ETDRS grid at Month 6 as measured by fluorescein angiogram (decrease is better)
| mm^2 | Immediate Cellular Therapy / Deferred Sham Therapy | Immediate Sham Therapy / Deferred Cellular Therapy |
|---|---|---|
| Change in Area of Non-perfusion Within ETDRS Grid | 1.4 ± 2.54 | -3.3 ± 6.32 |
Mean change from baseline of area of non-perfusion within Networc grid at Month 6 as measured by fluorescein angiogram (decrease is better)
| mm^2 | Immediate Cellular Therapy / Deferred Sham Therapy | Immediate Sham Therapy / Deferred Cellular Therapy |
|---|---|---|
| Change in Area of Non-perfusion Within Networc Grid | 0.2 ± 152.70 | 28.0 ± 53.61 |
Collected over Baseline to Month 12. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Immediate Cellular Therapy / Deferred Sham Therapy: Months 0-6 | 0/7 (0%) | 0/7 (0%) | 7/7 (100%) |
| Immediate Sham Therapy / Deferred Cellular Therapy: Months 0-6 | 0/9 (0%) | 1/9 (11.1%) | 9/9 (100%) |
| Immediate Cellular Therapy / Deferred Sham Therapy: Months 6-12 | 0/7 (0%) | 1/7 (14.3%) | 7/7 (100%) |
| Immediate Sham Therapy / Deferred Cellular Therapy: Months 6-12 | 0/9 (0%) | 0/9 (0%) | 9/9 (100%) |
| Event | Immediate Cellular Therapy / Deferred Sham Therapy: Months 0-6 | Immediate Sham Therapy / Deferred Cellular Therapy: Months 0-6 | Immediate Cellular Therapy / Deferred Sham Therapy: Months 6-12 | Immediate Sham Therapy / Deferred Cellular Therapy: Months 6-12 |
|---|---|---|---|---|
| Vitreous haemorrhageEye disorders | 0/7 | 0/9 | 1/7 | 0/9 |
| Iris NeovascularizationEye disorders | 0/7 | 0/9 | 1/7 | 0/9 |
| AppendicitisInfections and infestations | 0/7 | 1/9 | 0/7 | 0/9 |
| Event | Immediate Cellular Therapy / Deferred Sham Therapy: Months 0-6 | Immediate Sham Therapy / Deferred Cellular Therapy: Months 0-6 | Immediate Cellular Therapy / Deferred Sham Therapy: Months 6-12 | Immediate Sham Therapy / Deferred Cellular Therapy: Months 6-12 |
|---|---|---|---|---|
| Vitreous floatersEye disorders | 6/7 | 1/9 | 0/7 | 9/9 |
| Eye irritationEye disorders | 5/7 | 4/9 | 3/7 | 4/9 |
| Eye painEye disorders | 4/7 | 2/9 | 3/7 | 4/9 |
| Foreign body sensation in eyesEye disorders | 2/7 | 3/9 | 4/7 | 4/9 |
| Ocular hyperaemiaEye disorders | 3/7 | 3/9 | 4/7 | 5/9 |
| Dry eyeEye disorders | 2/7 | 4/9 | 0/7 | 2/9 |
| Visual impairmentEye disorders | 3/7 | 1/9 | 3/7 | 2/9 |
| FallInjury, poisoning and procedural complications | 0/7 | 3/9 | 0/7 | 0/9 |
| Immunisation reactionInjury, poisoning and procedural complications | 1/7 | 3/9 | 1/7 | 3/9 |
| Vision blurredEye disorders | 1/7 | 1/9 | 2/7 | 1/9 |
| Age, Categorical(Participants) | Immediate Cellular Therapy / Deferred Sham Therapy | Immediate Sham Therapy / Deferred Cellular Therapy | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 5 | 7 |
| >=65 years | 5 | 4 | 9 |
| Age, Continuous(years) | Immediate Cellular Therapy / Deferred Sham Therapy | Immediate Sham Therapy / Deferred Cellular Therapy | Total |
|---|---|---|---|
| Mean | 67.9 ± 12.59 | 62.7 ± 12.62 | 64.9 ± 12.47 |
| Sex: Female, Male(Participants) | Immediate Cellular Therapy / Deferred Sham Therapy | Immediate Sham Therapy / Deferred Cellular Therapy | Total |
|---|---|---|---|
| Female | 3 | 2 | 5 |
| Male | 4 | 7 | 11 |
| Ethnicity (NIH/OMB)(Participants) | Immediate Cellular Therapy / Deferred Sham Therapy | Immediate Sham Therapy / Deferred Cellular Therapy | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 7 | 8 | 15 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Immediate Cellular Therapy / Deferred Sham Therapy | Immediate Sham Therapy / Deferred Cellular Therapy | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 2 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 7 | 7 | 14 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — TRUST will follow specific plans for sharing of research data under the guidance of NIH's 2003 Data Sharing Policy. After analysis, the final data set can be provided after appropriate procedures are implemented to preserve the anonymity of the records, specifically where protected health information (PHI) is required. Upon request, anonymized data will be shared under confidentiality agreements with researchers interested in the project.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Time Frame will be determined.
Access criteria: Confidentiality agreements will be required before anonymized data will be shared.
Ran from Oct 2019 to primary completion in Nov 2023, 48 months.
Results were first posted in Dec 2024, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Emmes Company, LLC